Bionyra Pharma emerged from stealth with $165 million to develop immune disorder therapeutics centered on TL1A. The startup, co-founded by Sofinnova Partners and Frédéric Marrache (formerly Sanofi’s immunology R&D head), launched with three licensed assets from China and the U.S., with two programs already in Phase 1 studies. BYN-002 is a monoclonal antibody targeting TL1A designed for inflammatory diseases with an extended half-life profile, while BYN-003 pairs TL1A with IL-23 in a bispecific approach. Bionyra’s third asset, BYN-001, is an anti–IL-25 monoclonal antibody planned for studies including atopic dermatitis. The launch situates TL1A inhibition among a growing set of next-generation immunology targets, competing in markets where IL-23 inhibitors, JAK inhibitors, and integrin therapies have shaped standard-of-care. Bionyra’s early clinical progression and half-life strategy will be key to differentiation. The funding also signals continued investor appetite for antibody platforms that can deliver infrequent dosing and potentially better response profiles in immune-mediated conditions.